RxDoctor Payments Data

Tammy Smithson

Adult Health · Barberton, OHNPI 1306361084

Payments from drug & device makers

$2,039in general payments, 2019–2025

Across 107 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$440
  • AstraZeneca$367
  • Boehringer Ingelheim$147
  • Pulmonx Corporation$142
  • Amgen$141
  • Regeneron Healthcare Solutions, Inc.$131
  • plus $672 from 17 others

What the payments were for

  • Food & beverage$2,039100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,039 in reported general payments places this provider in the 80th percentile of 1,184 adult health providers in Ohio.

See all adult health providers in Ohio

Medicare billing

Part B allowed, 2024
$12,847
Medicare patients
93
Services billed
134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter259$276,992
Breztri AerosphereBudesonide/Glycopyr/Formoterol134$126,239
XolairOmalizumab20$61,258
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr46$39,563
Stiolto RespimatTiotropium Br/Olodaterol Hcl70$39,492
Breo ElliptaFluticasone/Vilanterol43$30,057
Spiriva RespimatTiotropium Bromide40$28,966
Albuterol Sulfate HfaAlbuterol Sulfate309$9,235
DuleraMometasone/Formoterol13$6,527
Bevespi AerosphereGlycopyrrolate/Formoterol Fum13$6,487
Advair HfaFluticasone Propion/Salmeterol14$5,681
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate25$5,423
SymbicortBudesonide/Formoterol Fumarate17$4,164
Ventolin HfaAlbuterol Sulfate30$3,530
Varenicline Tartrate15$3,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$440$346,612348 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$367$136,890164 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$147$68,458110 claims
MerckDulera$58$6,52713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,184 adult health providers in Ohio.

Other adult health in Barberton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →